Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, representing a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA increased by 21%, reaching around $234 million, with a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating expenses rose by 10.9% to approximately $1,360 million [11] - The pro forma net loss was reported at $4.2 million, influenced by a foreign exchange loss of around $83 million [11][21] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and investments in technology [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth driven by a 21% increase in lab tests performed [16] - Corporate accounts remained flat, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [17] Market Data and Key Metrics Changes - The dental services market contracted, with a 5.5% decline in sales, attributed to increased competition and market dynamics [14] - The company noted that the market for elective medical services may be affected by changes in purchasing power due to recent fiscal measures [9] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [7][10] - There is a commitment to expanding genetic testing capabilities, with an initial investment of €3 million for advanced sequencing technology [9] - The company plans to maintain a stable trajectory while adapting to the evolving macroeconomic environment, with a cautious approach to capital expenditures [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the performance of new hospital units, expecting them to reach breakeven by the end of the year [25][26] - The company is closely monitoring the impact of rising energy costs and potential government measures on purchasing power [37][39] - Management aims to fulfill the budget presented to investors and is optimistic about operational improvements despite foreign exchange losses [40][52] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - Capital expenditures for the second half of the year are expected to remain low, with no significant investments planned [23][32] Q&A Session Summary Question: What is the negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by mid-year [25][26] Question: What is the estimated impact of VAT increases on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [29][30] Question: What are the expectations for capital expenditures? - Management confirmed that capital expenditures will be low, with no large investments planned for the third or fourth quarters [31][32] Question: How will rising energy costs affect the company? - Management stated that the impact of rising energy costs is minimal, estimating a potential annual impact of €1 to €2 million [37][38] Question: What is the outlook for the full year results? - Management aims to fulfill the budget presented earlier and is optimistic about operational performance despite challenges [40][41]

Financial Performance - The Group achieved a consolidated pro-forma turnover of RON 1.57 billion in H1 2025, a 20.3% increase compared to H1 2024 [19] - Pro-forma EBITDA increased by 21.2% to RON 234.2 million, with a margin of 16.1% [34] - IFRS Revenues recorded a solid 20% increase, with 16.2% driven by organic growth [50] - Net cash from operating activities declined by 41% compared to the same period last year [60] Acquisitions and Investments - The Group finalized the acquisition of Routine Med Group in Tulcea in February [21] - A majority stake in All Clinic in the Republic of Moldova was acquired in March [21] - The acquisition of Medstar Clinic Group in Cluj-Napoca was announced in June, with 2024 revenues of approximately RON 32 million [22] - The company launched the first AI assistant integrated into its mobile app [25] - The company enhanced its diagnostic infrastructure with the 2nd automated laboratory line in the Group, with an investment of over EUR 2 million [26] - The company acquired the Illumina sequencing technology with an initial investment of EUR 3 million [27] Operational KPIs - Hospitals revenue increased by 37.8% to RON 437.787 million [50] - Clinics revenue increased by 20.3% to RON 586.623 million [50] - Laboratories revenue increased by 18.4% to RON 172.790 million [50]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Macy's due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] Earnings Expectations - Macy's is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year decrease of 64.2% [3] - Revenue projections stand at $4.74 billion, which is a 4% decline from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 8.62% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +7.53% suggests analysts have recently become more optimistic about Macy's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - Macy's currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Macy's exceeded the expected earnings of $0.14 per share by delivering $0.16, resulting in a surprise of +14.29% [13] - Over the past four quarters, Macy's has beaten consensus EPS estimates three times [14] Conclusion - While Macy's is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [17]

Core Viewpoint - Myriad Uranium Corp. is initiating a follow-on non-brokered private placement financing to raise $125,000 by issuing 500,000 units at $0.25 per unit, with proceeds intended for general working capital [1][2]. Group 1: Financing Details - The financing will consist of 500,000 units, each unit comprising one common share and one-half of a common share purchase warrant, with each full warrant allowing the purchase of one share at an exercise price of $0.35 for 24 months [1]. - The financing is being conducted to meet the investment requirements of a key institutional investor [2]. - Securities issued will be subject to a four-month hold period in accordance with Canadian securities laws [2]. Group 2: Company Overview - Myriad Uranium Corp. holds a 75% interest in the Copper Mountain Uranium Project in Wyoming, which has historical uranium deposits and mines, including the Arrowhead Mine that produced 500,000 lbs of U3O8 [4]. - The Copper Mountain project has seen extensive drilling, with approximately 2,000 boreholes drilled, indicating significant exploration potential [4]. - The company has also acquired a 100% interest in the Red Basin Uranium Project in New Mexico, which has a near-surface historical resource with grades ranging from 1,700 to 3,100 ppm [4]. Group 3: Additional Interests - Myriad holds a 50% interest in the Millen Mountain Property in Nova Scotia, Canada, with the other 50% held by Probe Gold Inc. [5].

All right, joining us right now with more on the retail sector is Manny Cher, LNK partner, BCI Brands chairman, and former PVH chair and CEO. Manny, first of all, thanks for being here. Why don't you break this all down for us.What for for us. What are you going to be looking for from these earnings results. How much do you think we'll see on the tariffs front. How much do you think we'll see about the strength of the consumer.>> I think um business has been good through the se through the second quarter. I ...

Company Overview - FabScrap is a small fashion nonprofit in Brooklyn that resells and recycles leftover fabric, aiming to reduce textile waste in landfills [1] - The organization collaborates with various brands, including household names like J Crew and Macy's, as well as niche brands like Noah [2] - FabScrap employs a small team of 15 people [6] Environmental Impact - FabScrap has saved 2 million pounds (907,185 kg) of textiles from landfills [1][3] - The nonprofit shares data with brands, including the amount of material saved from landfills, the percentage of materials reused, and the amount of CO2 saved [3] - The organization receives 6 to 7 thousand pounds (2,721 to 3,175 kg) of material every week [3] Operations and Processes - FabScrap sorts through thousands of pounds of textiles with the help of volunteers [4] - The organization recycles, resells, or downcycles excess material [2] - Smaller scraps of fabric are shredded and made into shoddy, which is used for insulation [5] - Fabric pieces too big to shred are sold to the public in a thrift store [6]

Core Viewpoint - Myriad Uranium Corp. and Rush Rare Metals Corp. have signed a letter of intent for a proposed merger, where Myriad will acquire 100% of Rush's outstanding shares, with a share exchange ratio of one Myriad share for every two Rush shares [1][2][3] Company Overview - Myriad Uranium Corp. is a uranium exploration company with a 75% interest in the Copper Mountain Uranium Project located in Wyoming, USA, which has historical uranium deposits and mines [5][6] - Rush Rare Metals Corp. is involved in the merger with Myriad, which aims to consolidate ownership of the Copper Mountain Project for enhanced value [2][3] Merger Details - Under the proposed arrangement, all of Rush's convertible securities will be converted to Myriad shares, and Rush will create a subsidiary, Rush Spinco, to hold its Boxi Property in Quebec [1][2] - The merger is expected to provide Rush shareholders with shares in both Myriad and Rush Spinco, allowing them to retain an interest in the Boxi property [3][4] Strategic Rationale - Both companies believe that unified ownership of the Copper Mountain Project will significantly increase its value and attract institutional investors [3] - Myriad's management emphasizes the historical investment and data supporting the potential of Copper Mountain as a district-scale uranium source for the U.S. [3][6] Conditions for Closing - The transaction is subject to several conditions, including mutual due diligence, execution of a definitive agreement, and approvals from Rush shareholders, the British Columbia Supreme Court, and the Canadian Securities Exchange [4]

Core Insights - Macy's has a strong history of beating earnings estimates and is well-positioned for future earnings success [1][2] - The average surprise for Macy's in the last two quarters was 15.21%, indicating consistent performance above expectations [2] - Macy's current Earnings ESP is +8.70%, suggesting analysts are optimistic about the company's earnings prospects [8] Earnings Performance - In the most recent quarter, Macy's reported earnings of $0.14 per share against an expectation of $0.16, resulting in a surprise of 14.29% [2] - For the previous quarter, Macy's exceeded the consensus estimate of $1.55 per share by reporting $1.80, achieving a surprise of 16.13% [2] Earnings ESP and Zacks Rank - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high likelihood of another earnings beat, with a success rate of nearly 70% for stocks with this profile [5][6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]

Core Viewpoint - Macy's stock has experienced a decline of 2.99% in the latest trading session, underperforming compared to major indices, despite a significant increase of 17.67% over the past month [1] Financial Performance - The upcoming earnings report for Macy's is projected to show an EPS of $0.18, reflecting a 66.04% decrease year-over-year, with revenue expected to be $4.74 billion, down 4.03% from the same quarter last year [2] - For the entire year, earnings are forecasted at $1.78 per share and revenue at $21.27 billion, indicating declines of 32.58% and 4.57% respectively compared to the previous year [3] Analyst Estimates - Changes in analyst estimates for Macy's are crucial as they reflect short-term business trends, with positive revisions indicating a favorable outlook on business health and profitability [4] - The Zacks Rank system, which considers estimate changes, currently rates Macy's at 4 (Sell), indicating a less favorable outlook [6] Valuation Metrics - Macy's is trading at a Forward P/E ratio of 7.69, significantly lower than the industry average of 17.2, suggesting that the stock is trading at a discount [7] - The Retail - Regional Department Stores industry, to which Macy's belongs, ranks in the bottom 22% of all industries, with a current Zacks Industry Rank of 194 [7][8]

Core Insights - Myriad Uranium Corp. has entered into three service agreements for investor relations services, enhancing its strategic communication and visibility in the uranium sector [1][2][3] Group 1: Service Agreements - Myriad has signed a Service Agreement with Departures Capital Inc. for strategic consulting and investor communications, effective July 16, 2025, for a one-year term, with a payment of US$25,000 (approximately C$34,500) [1] - A Service Agreement with SOMA Public Relations has been established for strategic communications services from August 1, 2025, to November 30, 2025, totaling $30,000 ($7,500 per month) [2] - Myriad has also entered into a Professional Services Agreement with HoldCo Markets Advisory Inc. for research and social media services, effective July 15, 2025, for one year, with a total payment of $39,600 ($3,300 per month) [3] Group 2: Project Developments - The CEO of Myriad highlighted the potential of the Copper Mountain Uranium Project, indicating that recent assays show significantly higher uranium grades than previously reported, suggesting the presence of more mineralization than initially thought [4] - The project has a historical investment of C$117 million (2024 dollars) in exploration and development, with over 2,000 historical boreholes drilled [4][10] - Myriad is conducting an additional ~1,500 assays to potentially upgrade existing intervals and expand the project's scale and grade [4] Group 3: Historical Estimates and Resources - Historical estimates related to the Copper Mountain Project are considered relevant but should not be relied upon as current mineral resources or reserves, as they have not been verified by a qualified person [5][6] - The nature of the mineralization at Copper Mountain presents inherent limitations in estimating resources from drill data [6][7] - A program of digitization and re-logging or re-drilling is required to verify historical estimates and establish current resources [8]